These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Pikman Y; Levine RL Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464 [TBL] [Abstract][Full Text] [Related]
8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T; Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279 [TBL] [Abstract][Full Text] [Related]
9. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Wehmeier A; Südhoff T; Meierkord F Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357 [TBL] [Abstract][Full Text] [Related]
10. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. Falanga A; Marchetti M; Schieppati F Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455 [TBL] [Abstract][Full Text] [Related]
11. Thrombocytosis and Thrombosis: Is There Really a Correlation? Galvez C; Stein BL Curr Hematol Malig Rep; 2020 Aug; 15(4):261-267. PubMed ID: 32399765 [TBL] [Abstract][Full Text] [Related]
12. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders. Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311 [TBL] [Abstract][Full Text] [Related]
13. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Barbui T; Finazzi G Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889 [TBL] [Abstract][Full Text] [Related]
14. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms. Koschmieder S Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290 [TBL] [Abstract][Full Text] [Related]
15. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. Goette NP; Lev PR; Heller PG; Kornblihtt LI; Korin L; Molinas FC; Marta RF Cytokine; 2010 Jul; 51(1):67-72. PubMed ID: 20483636 [TBL] [Abstract][Full Text] [Related]
16. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study. Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850 [TBL] [Abstract][Full Text] [Related]
17. How to manage children and young adults with myeloproliferative neoplasms. Barbui T Leukemia; 2012 Jul; 26(7):1452-7. PubMed ID: 22252311 [TBL] [Abstract][Full Text] [Related]
18. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. De Stefano V; Teofili L; Leone G; Michiels JJ Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199 [TBL] [Abstract][Full Text] [Related]